Published in Pharma Investments, Ventures and Law Weekly, July 30th, 2006
The financing was led by Venrock Associates, which joined founding investors Atlas Venture, Flagship Ventures, and Polaris Venture Partners in the round. As part of this financing Anders Hove, MD, of Venrock Associates will join the Adnexus board of directors. Adnexus is a private biotechnology company developing a breakthrough class of protein therapeutics known as AdNectins.
"Cancer, diabetes, inflammatory diseases and many other medical conditions continue to need alternatives to existing therapeutics. The novel class of therapeutics,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.